[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638305":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":28,"collaborators":7,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":7,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":7,"enrollmentInfo":41,"targetDuration":7,"studyType":44,"phases":7,"briefSummary":45,"conditions":46,"keywords":49,"overallStatus":55,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Lu Xie, M.D.","CONTACT","+8613401044719","xie.lu@hotmail.com",[15],{"facility":16,"status":7,"city":17,"state":7,"zip":7,"country":18,"countryCode":19,"cosmosGeoPoint":20,"geoPoint":25,"contacts":26},"Peking University People's Hospital, Beijing, Beijing 100044","Beijing","China","CN",{"type":21,"coordinates":22},"Point",[23,24],116.39723,39.9075,{"lat":24,"lon":23},[27],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"type":29,"investigatorFullName":30,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Xie Lu","Principal Investigator","100638305","neoadjuvant-radiotherapy-and-surgery-for-high-risk-localized-ewing-sarcoma-100638305",false,"NCT07620431","Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma","An Observational Study on the Safety and Efficacy of Neoadjuvant Concurrent Chemoradiotherapy Sequential Surgery for High-Risk Localized Ewing Sarcoma","Inclusion Criteria:\n\n1. The subject or their legal representative signs the written informed consent prior to enrollment.\n2. Age \\\u003C= 55 years old.\n3. Histologically confirmed Ewing sarcoma, with FET family (including EWSR1 or FUS) gene rearrangement confirmed by FISH or NGS. Clear FET-non ETS fusion cases are excluded.\n4. Deemed difficult to achieve a satisfactory surgical margin by 2 or more senior musculoskeletal oncologists.\n5. ECOG Performance Status: 0-1.\n6. Expected life expectancy \\>= 3 months.\n7. Women of childbearing potential must have a negative pregnancy test within 1 week prior to enrollment and agree to use contraception; male subjects must agree to use contraception or have undergone surgical sterilization during the study.\n\nExclusion Criteria:\n\n1. No opportunity for surgical resection after neoadjuvant chemotherapy.\n2. Extensive metastasis with no indication for local surgical resection.\n3. Uncontrolled concurrent medical conditions.\n4. Prior radiotherapy to the surgical site during front-line treatment.\n5. History of other malignant tumors within the past 5 years.\n6. Inability to cooperate with preoperative neoadjuvant radiotherapy (e.g., due to psychiatric factors).\n7. Any condition that, in the investigator's judgment, might harm the patient or prevent compliance with study requirements.","ALL","12 Months",{"count":42,"type":43},55,"ESTIMATED","OBSERVATIONAL","This is a single-center, single-arm, prospective observational study to evaluate the long-term local control rate, safety, and efficacy of preoperative neoadjuvant radiotherapy (36-45 Gy) followed by sequential radical surgery and postoperative chemotherapy in patients with high-risk, resectable localized Ewing sarcoma.",[47,48],"Ewing Sarcoma","Bone Neoplasms",[50,51,52,53,54],"Neoadjuvant Radiotherapy","Preoperative Radiotherapy","Observational Study","Local Control Rate","Wound Healing","NOT_YET_RECRUITING","2026-05-27",{"date":58,"type":59},"2026-06-02","ACTUAL",{"date":61,"type":43},"2026-06-01",{"date":63,"type":43},"2027-12-01",{"name":5,"class":6},1]